Summary This study was performed in order to analyse whether the immune unresponsiveness to My cobacterium leprae, largely seen in lepromatous patients, persisted after discharge from treatment. Lymphoproliferation and skin tests were performed using two mycobacterial antigens (M. lep rae and BeG) in three groups oflepromatous patients grouped by treatment status. Forty-seven per cent of the lepromatous patients tested acquired reactivity to M. leprae after long-term treatment.
Lepromatous leprosy patients (LL or BL fo rms) display a selective immunological unresponsiveness to My cobacterium leprae antigen with the absence of delayed-type hypersensitivity, I T-cell proliferation, 2 and deficiency in the production of growth factors such as IL-2. 3 These patients also fail to produce interferon-gamma (IFN-y) in response to M. leprae. 4 Active suppression by macrophages and/or T cells may explain their inability to respond to leprosy bacilli. 5 , 6 Lepromatous patients carry a high load of bacilli which may play a role in vivo in the induction of immune tolerance. 7 Cellular anergy observed in lepromatous patients appears to be M. leprae specific since the immune response against other antigens is largely normal. s
The effect of treatment on the recovery from the immunological anergy in lepromatous patients is a controversial subject. Findings from a number of studies suggest that an unresponsiveness to M. leprae seen in lepromatous patients is long-lasting and unrelated to the bacterial load. 9 • lo However, some studies have revealed different immunological reactivity to mitogens and mycobacterial antigens when cellular immune responses of short-term treated patients were compared with untreated patients.
I I-IS
To determine the effect of long-term treatment on the immune status of patients, we have assessed the cellular immune responses of 64 lepromatous patients to M. leprae and to BCG.
Materials and methods

PATIENTS
Sixty-four multi bacillary leprosy patients who attended the Outpatient Unit of the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, were included in this study. Forty-one patients were diagnosed as borderline lepromatous (BL) and twenty-three were classified as polar lepromatous (LL) according to Ridley-Jopling classification. 16 The patients were grouped by length of treatment. Twenty-four patients were recently diagnosed and had received no treatment (NT) at the time of the study. Twenty-five patients were on multidrug therapy, ranging from 2 to 15 months (on treatment, OT). Fifteen patients had received mono therapy with dapsone from between 10 to 30 years (mean 16·6 years) and had terminated therapy from 1 to 6 years prior to participation in this study. Patients in this group, designated AT (after treatment) were without lesions and had negative lymph smears for acid-fast bacilli (AFB). None of the patients included in this study presented episodes of reaction during the study.
LE PROMIN SKIN TEST
Armadillo-derived lepromin (NHDC, Carville, USA, 3-4 x 10 7 bacilli/ml) was injected intradermally in the fo rearm and the reaction was measured 3 to 4 weeks after the injection (late lepromin reaction). Induration ;;:: 3 mm was considered positive.
L YMPHOPROLIFERA TION ASSAY
Heparinized blood was collected under sterile conditions from the patients and mononuclear leukocytes (PBL) were isolated by Ficoll-Hypaque gradient centrifugation. The cells were resuspended in RPM I 1640 (Gibco Lab.) supplemented with 10% human AB serum, 100 U/ml penicillin and 100 jig/ml streptomycin and 2 mM L-glutamine (complete medium). All proliferation assays were performed in microtitre wells in a final volume of 0·2 ml complete medium. Stimulation with antigen was carried out for 6 days at 37°C in a 5% CO 2 atmosphere . For these experiments, 2 x 10 5 PBL were incubated with 20 jig/ml M. leprae, or 25 jig/ml BCG in triplicate. One jiCi per well of [ 3 H]thymidine (Amersham Co., specific activity 6·7 Ci/mM) was added 18 h before harvesting cells for measurement of radio labelled thymidine incorporated into newly synthesized DNA. The results are expressed as stimulation index (SI) derived as the ratio of mean cpm cultures with antigen to the cpm of cultures without antigen. Proliferation to the antigen was considered positive for SI ;;:: 3·0.
ANTIGENS
M. leprae was kindly provided by Dr R. J. W. Rees (IMMLEP Bank, Mill Hill, England) and BCG was obtained from the Ataulfo de Paiva Foundation, Rio de Janeiro, Brazil.
STATISTICAL ANALYSIS
For comparison of the cellular immune response to M. leprae and BeG among the groups, Student's {-test and the Mann-Whitney test were used.
Results
LE PROMIN TEST
As expected, all the patients in NT and OT groups showed a negative lepromin skin test. In AT group, four patients developed a skin-test reaction; however, no correlation with the duration of treatment was noted (Table 1) . Before the onset of treatment all patients in the AT group had negative skin tests (data not shown).
L YMPHOPROLIFERA TION ASSAY
The number of M. leprae nonresponders was significantly lower in the AT group in comparison to that of the NT and OT patients (p < 0·05). Of the A T patients 53·4% were unresponsive to M. lep rae (SI < 3·0) ( Figure 1 ). In contrast, 95·8% and 92% of the NT and OT patients, respectively, failed to respond to leprosy bacilli. There was no difference between the response of LL and BL patients in any of the groups studied. However, a significant difference was fo und between the mean SI of AT group as compared to the NT Relationship between treatment and response to Mycobacterium leprae. PBL from patients after treatment (A T) (n = 15), on treatment (OT) (n = 25), and untreated (NT) (n = 25) were stimulated with M. leprae or BCG. Proliferation to antigen was considered negative for SI < 3·0. Figure I . A SI 2: 3 was considered a positive response. There was a significant difference between the response to My cobacterium /eprae (P < 0'05) and BCG (P < 0'02), when the A T group was compared to NT and OT groups (Student's t-test).
and OT patients (p < 0,05). The AT group mean SI was 4·2 (ranging from 0·9 to ) 8·8) in comparison to mean SI of 1·5 (ranging from 0·5 to 3·0) in the NT group and 1·04 (ranging from 0·2 to 4·0) among the OT group (Figure 2 ). To determine whether the duration of treatment was correlated to the M. /ep rae response in the AT patients, we divided this group into responders and nonresponders. Among the 8 (53,3%) responder patients, the mean treatment time was 16·2 ± 4· 5 years, while in the group that remained unresponsive, the mean duration of treatment was 17·0 ± 5·0 years. No statistical difference was observed between the nonresponder and responder patients with regard to the duration of treatment before their lymph smear became AFB negative (8'7 ± 5·3 years for the responder patients vs. 8·3 ± 5·2 years for the nonresponders).
During the course of these studies, two M. leprae responsive patients from the AT group developed lesions clinically and histologically compatible with indeterminate leprosy, and rare AFB was seen in the skin biopsies (Table 1) . With regard to reactional states, it is important to note that 7 patients (46·6%) of the AT group had erythema nodosum leprosum during their course of treatment. All but one showed a positive response to M. leprae in this study.
Stimulation with BeG, similarly, evoked a higher response in PBL from patients in the AT group as compared to the OT and NT groups (p < 0·02). As shown in Figure 2 , the mean SI for AT patients was 7·52 compared to 3·44 and 4·20 in the OT and NT patients. All patients showing a positive response to M. leprae (I patient in the NT group, 2 patients in the OT group, and 7 patients in the AT group) were also responsive to BeG.
Discussion
The present study supports previous findings concerning the lack of cellular immune response to M. leprae in LL and BL patients. While the majority (80·7%) of the patients included in this study did not respond to M. leprae (SI < 3·0%), only 30% were unresponsive to BeG. However, when patients from the whole spectrum of leprosy were compared to household contacts, a good correlation was fo und between the response to M. leprae and BeG. 1 7
When lepromatous patients were grouped by their treatment status, the percentage of M. leprae nonresponders was significantly lower among the long-term treated patients (AT) compared to untreated, newly diagnosed patients (NT) and the short-term treated (OT) patients. Likewise, the number of BeG responsive patients also increased after treatment. The number of responder patients was higher, and an intensified response was observed to both M. leprae and BeG as evaluated by the mean SI. This is another indication that the continuous presence of mycobacteria could contribute to the depression of the host's cellular immunity.
The improved immune response to BeG demonstrated that the unresponsiveness in lepromatous patients is not restricted to M. leprae. Reitan et al. ls have, similarly, observed that PPD evokes a stronger reaction in PBL from treated patients as compared to the untreated leprosy patients. An improved response to mitogens in treated patients has also been reported. 19 The long-lasting unresponsiveness seen in almost half of the long-term treated patients might support the hypothesis which attributes the absence of responsiveness in LL patients to genetic fa ctors, 20 absence of M. leprae-reactive T cells from the circulation I or the presence of suppressor mechanisms. 5 • 6 However, reversion of the unresponsiveness of lepromatous patients has been documented in many reports under different clinical and experimental conditions. 4. 7 . 9 . 14. 2 1 The immune reactivity observed after chemotherapy suggests that the unresponsive ness in lepromatous patients might not be long lasting and unchangeable in all cases. The inability to kill and clear bacteria during the early phase of infection could result in a high antigenic load which may in turn induce a tolerant state. Recent studies have demo,nstrated that immune tolerance may develop in the presence of a high concentration of antigens 22 and this state may be reversed after decreasing the antigenic load. 23 The fact that many of the M. leprae patients in the AT group had previously presented episodes of ENL during the course of treatment raises the hypothesis that M. leprae-reactive T cells had emerged during the reactional stages. 2 4 Waldorf et al. 2 5 have reported similar findings using skin tests to assess immune responses in leprosy patients. Lepromatous patients with ENL showed higher positivity to DNCB sensitization as compared to patients without ENL.
Taken together, findings from the present investigation support the hypothesis that reduction in M. leprae post-therapy may contribute to the reversal of unresponsiveness in some lepromatous patients.
